Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
2.400
-0.200 (-7.69%)
At close: Apr 14, 2026
Silence Therapeutics Revenue
In the year 2025, Silence Therapeutics had annual revenue of $559.00K, down -98.71%. Silence Therapeutics had revenue of $34.00K in the quarter ending December 31, 2025, a decrease of -99.86%.
Revenue
559.00K
Revenue Growth
-98.65%
P/S Ratio
517.12
Revenue / Employee
6.35K
Employees
88
Market Cap
289.07M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 559.00K | -42.70M | -98.71% |
| Dec 31, 2024 | 43.26M | 11.62M | 36.71% |
| Dec 31, 2023 | 31.64M | 9.99M | 46.12% |
| Dec 31, 2022 | 21.66M | 4.87M | 29.01% |
| Dec 31, 2021 | 16.79M | 9.29M | 124.07% |
| Dec 31, 2020 | 7.49M | 7.17M | 2,215.11% |
| Dec 31, 2019 | 323.57K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 21.62K | -928.69K | -97.72% |
| Dec 31, 2016 | 950.31K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 23.37K | -170.40K | -87.94% |
| Dec 31, 2013 | 193.77K | -70.63K | -26.71% |
| Dec 31, 2012 | 264.40K | -812.57K | -75.45% |
| Dec 31, 2011 | 1.08M | -2.61M | -70.75% |
| Dec 31, 2010 | 3.68M | 893.28K | 32.03% |
| Dec 31, 2009 | 2.79M | -435.52K | -13.51% |
| Dec 31, 2008 | 3.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 237.26M |
| BioStem Technologies | 47.48M |
| Nuo Therapeutics | 3.31M |
| Northwest Biotherapeutics | 937.00K |
| Harvard Apparatus Regenerative Technology | 704.00K |
| Provectus Biopharmaceuticals | 336.11K |
| Arch Biopartners | 115.29K |
Silence Therapeutics News
- 5 weeks ago - Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 months ago - Silence Therapeutics Announces Leadership Changes - Business Wire
- 5 months ago - Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Business Wire
- 5 months ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 6 months ago - Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) - Business Wire
- 8 months ago - Silence Therapeutics to Participate in September Investor Conferences - Business Wire
- 8 months ago - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 10 months ago - Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera - Business Wire